The Body Pharm Retatrutide 32 pen is a pre-filled, dial-a-dose subcutaneous injection device containing 32mg of retatrutide β a triple agonist active at the GIP, GLP-1 and glucagon receptors β available through JCSG.org for Australian research accounts. Dial-a-dose markers sit at 2mg, 4mg and 8mg per click, and no reconstitution step is required: the pen ships ready for immediate laboratory use.
This profile documents the full specification on record: dose increments and inferred dose count; storage requirements and transport considerations; how the 32mg pen fits against the 64mg sibling; and the regulatory context that applies to Australian research procurement.
Key Takeaways
- The Body Pharm Retatrutide 32 pen is a pre-filled, multi-dose device with dial-a-dose markers at 2mg, 4mg and 8mg
- Retatrutide's triple-receptor mechanism (GIP + GLP-1 + glucagon) is mechanistically distinct from tirzepatide (dual) and semaglutide (mono), opening hepatic and lipolytic research pathways neither dual nor mono agonists reach
- The 32mg pen suits 4β12 week pilot studies and smaller cohorts; the 64mg variant extends to longer maintenance protocols
- Cold-chain transport above 25 Β°C for more than 24 hours can compromise peptide stability β JCSG.org ships with cold-chain packaging for Australian orders
What Is the Body Pharm Retatrutide 32 Pen?
The Body Pharm Retatrutide 32 pen is a pre-filled, multi-dose subcutaneous injection device containing 32mg of retatrutide β a triple agonist active at the GIP, GLP-1 and glucagon receptors β supplied for research and analytical purposes only.
Body Pharm's product copy describes the device as a "32mg multi-dosage injection pen" acting at "GIP, GLP-1 & glucagon receptor agonist for subcutaneous injection." The pen ships ready to inject, with no reconstitution step or bacteriostatic water required, and uses a dial-a-dose mechanism with fixed click positions at 2mg, 4mg and 8mg.
How the triple agonist mechanism differs from tirzepatide
Retatrutide engages three incretin and glucagon pathways simultaneously. Tirzepatide is a dual agonist active at GIP and GLP-1 only. That third arm β glucagon receptor activity β recruits hepatic energy expenditure and lipolytic signalling pathways that GIP and GLP-1 agonism do not directly engage. Researchers comparing the Body Pharm Tirzepatide 60 Pen against retatrutide pens are usually trying to characterise exactly this third-arm contribution.
The 32mg device is the lower-payload sibling of the Body Pharm Retatrutide 64 Pen, which doubles the reservoir while keeping the same click increments.
Full Product Specification
The table below consolidates the specification fields published across Body Pharm listings. Unverifiable fields are flagged.
| Specification | Value |
|---|---|
| Total peptide content | 32mg retatrutide |
| Pen format | Pre-filled, multi-dose dial-a-dose pen |
| Injection route | Subcutaneous |
| Dose increments (per click) | 2mg, 4mg, 8mg fixed markers |
| Maximum single dose | 8mg |
| Reconstitution required | None β pre-filled, ready to inject |
| Concentration (mg/mL) | Not published [unverified] |
| Total doses per pen | Not stated; implied 4 Γ 8mg or up to 16 Γ 2mg [unverified] |
| Storage temperature / shelf life | Not stated on 32mg listing [unverified] |
| Certificate of Analysis (batch purity) | Not published for this SKU [unverified] |
| Mechanism | Triple agonist: GIP, GLP-1, glucagon |
Four spec fields could not be independently confirmed from Body Pharm's own documentation as of May 2026: mg/mL concentration, exact dose count per pen, storage parameters, and batch-level Certificate of Analysis (CoA) data. Procurement officers who require batch-specific purity documentation for audit trails should request it at the time of order β contact JCSG.org support with your batch-documentation requirements.
Procurement officers cross-checking this device against the Body Pharm Retatrutide 64 Pen or the dual-agonist Body Pharm Tirzepatide 60 Pen should request batch documentation directly from JCSG.org. Retailer-sourced specifications often lack the batch-specific purity and stability data required for regulatory audit trails.
Storage and Handling Requirements
Body Pharm does not publish device-specific storage parameters for the Retatrutide 32mg pen as of May 2026. Australian researchers should treat any temperature or shelf-life figure quoted without a manufacturer insert or batch CoA as unverified.
General peptide-handling practice for pre-filled retatrutide pens suggests 2β8 Β°C refrigeration with light protection and limited room-temperature excursions, but this should be confirmed against the batch CoA for your specific unit.
The recommended intake protocol is to treat the 32mg pen as a 2β8 Β°C product, logging receipt temperature against a calibrated data logger and quarantining any unit that arrived outside that range pending supplier confirmation. Freeze-thaw cycles degrade triple-agonist peptide integrity and invalidate downstream assay data. The pen should never be placed in a domestic freezer or transported on dry ice without explicit manufacturer clearance β peptide backbone hydrolysis accelerates below β10 Β°C and renders the active unfit for research use.
Australian transport considerations
JCSG.org ships Australian orders with cold-chain packaging appropriate for incretin pens. Transit from overseas warehouses can cross climate zones above 30 Β°C in Australian summer. Procurement officers comparing this device with the Body Pharm Retatrutide 64 Pen or the Body Pharm Tirzepatide 60 Pen should request shipper temperature logs as part of acceptance testing. Excursions above 25 Β°C for more than 24 hours can compromise peptide stability and create audit liability if assay results later fall outside expected ranges.
32mg vs 64mg Pen: Side-by-Side Comparison
The Body Pharm Retatrutide 32 Pen holds half the peptide payload of the 64mg variant and suits shorter titration windows or single-cohort studies. The 64mg pen extends a 2 β 4 β 8mg weekly protocol further without a second device on hand. Rows marked [unverified] reflect gaps in the 2024β2026 public record.
| Attribute | 32mg pen | 64mg pen |
|---|---|---|
| Total peptide content | 32mg retatrutide | 64mg retatrutide |
| Doses per pen (8mg weekly) | ~4 weekly doses [unverified] | ~8 weekly doses [unverified] |
| Dose increments | Dial-a-dose, 2/4/8mg markers | Dial-a-dose, 2/4/8mg markers [unverified] |
| Maximum single dose | 8mg | 8mg [unverified] |
| Storage | 2β8 Β°C, light-protected (general peptide practice) [unverified] | 2β8 Β°C, light-protected [unverified] |
| Current price | See buy box | See buy box |
| Best-fit application | 4β12 week pilot studies, smaller cohorts | 12β16 week titration, multi-subject protocols |
When the 32mg pen is the better procurement choice
The 32mg SKU is ideal when a study design calls for a single titration arc (2mg β 4mg β 8mg over four to six weeks) and a second pen would leave unused peptide at study close. Unused inventory creates disposal compliance obligations and ties up research budget. It also suits procurement officers running parallel cohorts where each researcher holds an individually logged device β reducing the audit burden of shared 64mg inventory and simplifying chain-of-custody documentation.
When to step up to the 64mg
Choose the Body Pharm Retatrutide 64 Pen for protocols extending past eight weeks at maintenance dose, or where comparative arms against the Body Pharm Tirzepatide 60 Pen require matched study durations. Mismatched study lengths introduce confounding variables in mechanistic comparisons.
How Retatrutide Differs from Tirzepatide and Semaglutide
Retatrutide targets GIP, GLP-1, and glucagon receptors simultaneously. Tirzepatide acts on two (GIP + GLP-1) and semaglutide on one (GLP-1). That third receptor engagement is the mechanistic line separating this compound from the dual and mono agonists most procurement officers already know.
The glucagon receptor component makes retatrutide a distinct research substrate rather than a stronger version of tirzepatide. Glucagon receptor agonism is associated with increased hepatic energy expenditure and lipolytic signalling β a pathway that GLP-1 and GIP agonism do not directly recruit. For laboratory work, this means retatrutide protocols may be designed around energy-balance and hepatic endpoints in addition to the glycaemic and appetite-pathway readouts typical of semaglutide and tirzepatide studies.
Researchers running side-by-side mechanistic comparisons will usually pair the Body Pharm Retatrutide 32 Pen profile against the dual-agonist Body Pharm Tirzepatide 60 Pen. Where a GLP-1-only reference arm is needed, they use the Body Pharm Semaglutide 6 Pen.
Phase 3 efficacy figures circulating in 2026 commercial copy remain unpublished in peer-reviewed form. Mechanistic framing rather than outcome claims is the defensible position for procurement documentation β unpublished efficacy claims expose research institutions to regulatory and reputational risk if the data later diverge from published results.
Regulatory Context for Australian Researchers (2026)
Retatrutide is not approved by the Therapeutic Goods Administration (TGA) for human therapeutic use in Australia as of 2026. A search of the Australian Register of Therapeutic Goods returns no ARTG entry for the molecule under its INN or known code names. Approved incretin agonists on the ARTG in 2026 include semaglutide, tirzepatide, and dulaglutide; retatrutide is absent.
The Body Pharm Retatrutide 32 Pen and its sibling Body Pharm Retatrutide 64 Pen are marketed as research chemicals, supplied for in vitro and laboratory research. That framing exempts them from therapeutic goods scheduling in most jurisdictions.
TGA scheduling of peptides can change between Poisons Standard updates. Procurement officers should verify current scheduling at tga.gov.au immediately before any sourcing decision and obtain independent advice from an Australian regulatory professional or lawyer.
Research use only. This product is not approved for human therapeutic use. Regulatory status as of 2026 is stated as [unverified] pending direct confirmation against the current Poisons Standard and ARTG. Verify current scheduling at tga.gov.au before procurement.
Body Pharm Research Peptides
Body Pharm is a research peptide manufacturer with an extensive pen and vial catalogue. The full Body Pharm range available in Australia includes the Body Pharm BPC-157, Body Pharm CJC-1295 with DAC, Body Pharm MOTS-C 32 Pen, the dual-agonist Body Pharm Tirzepatide 60 Pen, and the higher-payload Body Pharm Retatrutide 64 Pen.
Batch-specific purity data and a manufacturer Certificate of Analysis for the 32mg pen are not published in any 2024β2026 indexed source [unverified] β contact JCSG.org if your institution requires batch documentation at order time.
Frequently Asked Questions
Is the Body Pharm Retatrutide 32 pen pre-filled or does it require reconstitution?
The Body Pharm Retatrutide 32 pen is supplied as a pre-filled, ready-to-inject subcutaneous device with no reconstitution step. Retailer documentation describes the unit as containing 32mg of already-solubilised retatrutide, attached to a standard pen needle before use. No 2024β2026 source references lyophilised powder or bacteriostatic water for this SKU.
How many doses does the 32mg pen contain?
Body Pharm does not publish a fixed dose count per pen, and the figure depends entirely on the weekly dial setting [unverified]. At the 2mg titration marker a 32mg reservoir theoretically supports up to sixteen weekly doses. At the 8mg maintenance setting it would be exhausted in roughly four weeks.
What is the difference between the 32mg and 64mg pen?
The 32mg pen carries half the total retatrutide payload of the Body Pharm Retatrutide 64 Pen, but both use the same dial-a-dose mechanism with 2mg, 4mg, and 8mg click markers. The 32mg unit suits shorter titration windows; the 64mg unit suits longer 8β12 week maintenance research at the upper dose.
Is retatrutide legal to buy in Australia?
Retatrutide is not listed on the Australian Register of Therapeutic Goods and has no entry in the current Poisons Standard as of 2026 [unverified]. It remains an investigational compound with no TGA-approved therapeutic product. Any procurement by Australian laboratories should be handled under unapproved-goods or research-use pathways rather than as a prescription medicine. Verify current scheduling at tga.gov.au before ordering.
How should the pen be stored after opening?
No Body Pharm insert specifying opened or unopened storage parameters for the 32mg pen is publicly indexed for 2024β2026 [unverified]. General peptide-handling practice suggests refrigeration at 2β8 Β°C with light protection [unverified]. Researchers comparing storage logistics against dual-agonist alternatives may also reference the Body Pharm Tirzepatide 60 Pen profile.
Where can I buy the Body Pharm Retatrutide 32 Pen in Australia?
The Body Pharm Retatrutide 32 Pen is available through JCSG.org, which ships to Australian research accounts with cold-chain packaging. Current pricing is shown in the buy box.
Procurement Notes
Before procurement, request a batch Certificate of Analysis at the time of order if your institution requires it. Confirm current TGA scheduling and Poisons Standard status at tga.gov.au before sourcing.
